Vyne Therapeutics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Vyne Therapeutics Inc Company

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Vyne Therapeutics Inc Info



Ticker SymbolVYNE

Company nameVyne Therapeutics Inc

IPO dateJan 25, 2018

CEOMr. David Domzalski

Number of employees13

Security typeOrdinary Share

Fiscal year-endJan 25

Address685 Route 202/206 N., Suite 301

CityBRIDGEWATER

Stock exchangeNASDAQ Capital Market Consolidated

CountryUnited States of America

Postal code08807

Phone18007757936

Websitehttps://vynetherapeutics.com/

Ticker SymbolVYNE

IPO dateJan 25, 2018

CEOMr. David Domzalski

Company Executives of Vyne Therapeutics Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

112.77K

-2.94%

Mr. Patrick G. Lepore

Lead Independent Director

51.47K

--

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

38.72K

-8.47%

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

28.16K

-8.01%

Mr. Steven L. Basta

Independent Director

7.45K

--

Ms. Sharon Barbari

Independent Director

--

Mr. David Domzalski

President, Chief Executive Officer, Director

--

Ms. Elisabeth A. Sandoval Little

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

112.77K

-2.94%

Mr. Patrick G. Lepore

Lead Independent Director

51.47K

--

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

38.72K

-8.47%

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

28.16K

-8.01%

Mr. Steven L. Basta

Independent Director

7.45K

--

Ms. Sharon Barbari

Independent Director

--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2024

FY2023

FY2022

FY2021

FY2020

By BusinessUSD

Name

Revenue

Proportion

Royalty revenues

501.00K

0.00%

No Data

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Royalty revenues

501.00K

0.00%

Shareholding Stats

Updated: Tue, Aug 19

Shareholders

Shareholder Types

Shareholders

Proportion

Cormorant Asset Management, LP

5.38%

Access Industries, Inc.

4.38%

Citadel Advisors LLC

4.08%

Acorn Capital Advisors, LLC

2.89%

Delaware Street Capital, L.L.C.

2.73%

Other

80.53%

Shareholders

Proportion

Cormorant Asset Management, LP

5.38%

Access Industries, Inc.

4.38%

Citadel Advisors LLC

4.08%

Acorn Capital Advisors, LLC

2.89%

Delaware Street Capital, L.L.C.

2.73%

Other

80.53%

Shareholder Types

Shareholders

Proportion

Hedge Fund

22.17%

Investment Advisor

8.71%

Corporation

4.38%

Investment Advisor/Hedge Fund

1.61%

Individual Investor

1.37%

Private Equity

1.24%

Research Firm

0.59%

Venture Capital

0.22%

Other

59.71%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

84

8.80M

34.54%

-586.92K

2025Q2

84

9.46M

56.76%

-1.30M

2025Q1

81

9.36M

56.20%

-1.38M

2024Q4

92

9.37M

63.49%

-533.87K

2024Q3

88

8.98M

61.30%

-594.32K

2024Q2

89

9.65M

66.73%

+287.65K

2024Q1

92

9.64M

67.66%

+101.95K

2023Q4

101

10.22M

72.71%

+4.63M

2023Q3

117

471.27K

14.37%

-340.06K

2023Q2

135

501.83K

15.37%

-314.68K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Cormorant Asset Management, LP

1.37M

5.38%

+1.37M

--

Jun 30, 2025

Access Industries, Inc.

1.12M

4.38%

--

Feb 14, 2025

Citadel Advisors LLC

1.04M

4.08%

-60.26K

-5.48%

Jun 30, 2025

Acorn Capital Advisors, LLC

736.57K

2.89%

-49.37K

-6.28%

Jun 30, 2025

Delaware Street Capital, L.L.C.

696.47K

2.73%

--

Sep 30, 2024

Adage Capital Management, L.P.

644.13K

2.53%

+300.00K

+87.18%

Jun 30, 2025

Dafna Capital Management, LLC

636.10K

2.5%

--

Jun 30, 2025

Kennedy Capital Management LLC

570.74K

2.24%

+492.70K

+631.35%

Jun 30, 2025

The Vanguard Group, Inc.

496.30K

1.95%

+20.65K

+4.34%

Jun 30, 2025

Palo Alto Investors LP

445.43K

1.75%

--

Jun 30, 2025

Related ETFs



Updated: Sun, Nov 2

Name

Proportion

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Date

Type

Ratio

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1